SCHEMBL3024893

SCHEMBL3024893

COc1cccc(-c2ccc3c(C(=O)Nc4onc(C)c4C)c(OC)ccc3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
HSD17B2 P37059 1/20 0.46
HPGD P15428 1/20 0.44
MAPT P10636 7/20 0.44
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TSHR P16473 2/20 0.42
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
GAA P10253 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
PLAU P00749 2/20 0.41
PLG P00747 1/20 0.41
PLAT P00750 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015227 0.81 TRPV1 (0.55) HSD17B1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL13210870 0.80 HSD17B1 (0.51) HSD17B1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL3014831 0.80 PLAU (0.57) HSD17B1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL3015172 0.79 HSD17B1 (0.67) HSD17B1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL3002889 0.79 HSD17B1 (0.47) HSD17B1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL3016129 0.78 TP53 (0.61) HSD17B1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL3019201 0.77 ALDH1A1 (0.57) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL3021168 0.76 HSD17B1 (0.60) HSD17B1HSD17B2HPGDMAPTHSD17B10
SCHEMBL3015936 0.76 HSD17B1 (0.56) HSD17B1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL3015306 0.72 SIRT2 (0.47) HSD17B1CYP1A2CYP3A4HSD17B2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546392-B2 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases UNIVERSITAET DES SAARLANDES (DE) 2013-10-01 US disclosed
US-8546392-B2 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases UNIVERSITAET DES SAARLANDES (DE) 2013-10-01 US disclosed
US-8546392-B2 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases UNIVERSITAET DES SAARLANDES (DE) 2013-10-01 US disclosed
US-20100204234-A1 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases UNIVERSITAET DES SAARLANDES (DE) 2010-08-12 US disclosed
US-20100204234-A1 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases UNIVERSITAET DES SAARLANDES (DE) 2010-08-12 US disclosed
US-20100204234-A1 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases UNIVERSITAET DES SAARLANDES (DE) 2010-08-12 US disclosed
WO-2008116920-A2 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES Universität des Saarlandes (DE) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204234-A1 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases HSD17B1, HSD17B11, HSD17B2 HSD17B1 1/4885CYP1A2 87/4885CYP3A4 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.